I believe Atea Pharmaceutical (AVIR) to be the most under-rated COVID-19 related biotech stock in the market to date. Their interim analysis data relating to treatment of COVID-19 is unmatched in the field.
With delta wave surging, many countries way behind on vaccinating and healthcare systems set for the toughest winter in living memory the stage is set for Atea’s AT-527 to be a worldwide phenomenon. Atea is hugely undervalued presently.
Interim virology results indicated that AT-527 rapidly reduced viral load levels. At Day 2, patients receiving AT-527 experienced a 0.7 log10 (80%) greater mean reduction from baseline viral load as compared to placebo.
A sustained difference in viral load reduction was maintained through Day 8. When evaluating a strict RT-qPCR threshold of 500 copies/mL with no detectable ribonucleic acid (RNA) virus, the AT-527 arm achieved SARS-CoV-2 clearance as early as Day 2 (in 6% of patients), Day 8 (in 7% of patients) Day 10 (in 33% of patients), and Day 12 (in 31% of patients) compared to 0% of patients in the placebo arm at the same timepoints. By Day 14 (last viral sampling study day) approximately 47% of patients in the AT-527 arm and 22% in the placebo arm had no detectable RNA virus (TND).
AT-527 was safe and well-tolerated in the study.
What’s next?
Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19 (MORNINGSKY) has a COMPLETION DATE of 3rd August 2023.
This article was written by u/DrBenC.
